Illumina, Inc. (ILMN) Given Average Recommendation of “Hold” by Brokerages

Illumina, Inc. (NASDAQ:ILMN) has earned a consensus rating of “Hold” from the twenty-five analysts that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $203.39.

Several brokerages recently weighed in on ILMN. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. Citigroup Inc. upped their target price on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Barclays PLC upped their target price on Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, October 25th. Bank of America Corporation upped their target price on Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a report on Wednesday, October 25th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and set a $205.00 target price (up from $200.00) on shares of Illumina in a report on Wednesday, October 25th.

In other news, Director Jay T. Flatley sold 22,540 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $195.21, for a total value of $4,400,033.40. Following the transaction, the director now directly owns 539,176 shares of the company’s stock, valued at $105,252,546.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $210.59, for a total transaction of $4,211,800.00. Following the completion of the transaction, the director now directly owns 536,717 shares in the company, valued at $113,027,233.03. The disclosure for this sale can be found here. Insiders sold 187,964 shares of company stock worth $38,454,069 over the last ninety days. 1.60% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Private Advisor Group LLC increased its position in Illumina by 7.6% during the third quarter. Private Advisor Group LLC now owns 5,898 shares of the life sciences company’s stock worth $1,198,000 after buying an additional 418 shares during the last quarter. Tredje AP fonden increased its position in Illumina by 1.1% during the third quarter. Tredje AP fonden now owns 65,356 shares of the life sciences company’s stock worth $13,019,000 after buying an additional 700 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its position in Illumina by 6.8% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 89,277 shares of the life sciences company’s stock worth $17,784,000 after buying an additional 5,647 shares during the last quarter. KBC Group NV increased its position in Illumina by 31.2% during the third quarter. KBC Group NV now owns 19,466 shares of the life sciences company’s stock worth $3,877,000 after buying an additional 4,632 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in Illumina by 4.9% during the third quarter. Schwab Charles Investment Management Inc. now owns 508,368 shares of the life sciences company’s stock worth $101,267,000 after buying an additional 23,647 shares during the last quarter. 92.70% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/11/14/illumina-inc-ilmn-given-average-recommendation-of-hold-by-brokerages.html.

Shares of Illumina (NASDAQ:ILMN) traded down $0.67 during trading on Monday, reaching $208.94. The company had a trading volume of 598,500 shares, compared to its average volume of 970,485. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The company has a market capitalization of $30,530.00, a price-to-earnings ratio of 61.09, a P/E/G ratio of 3.45 and a beta of 0.74. Illumina has a 1 year low of $119.37 and a 1 year high of $214.50.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. Illumina’s quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.97 earnings per share. equities analysts anticipate that Illumina will post 3.75 EPS for the current year.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply